Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation.

Molecular cancer research : MCR - 1 Mar 2017

Xie Xiaolei, He Guangan, Siddik Zahid H

Abstract excerpt

Dysfunctionality of the p53 tumor suppressor is a major cause of therapeutic drug resistance in cancer. Recently, we reported that mutant, but otherwise functional, p53v172F was inactivated in cisplatin-resistant 2780CP/Cl-16 and 2780CP/Cl-24 human ovarian tumor cells by increased recruitment of the inhibitor MDM4. The current study demonstrates that, unlike cisplatin, platinum analogues oxaliplatin and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cisplatin
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, p53

Share to HCT116 Cells

Share to Organoplatinum Compounds

Share to Ovarian Neoplasms

Share to Oxaliplatin

Source

Open in PubMed Open full text

Identifiers

PMID: 28031409
DOI: 10.1158/1541-7786.MCR-16-0257-T
PMCID: PMC5334359

Genes

MDM2
MDM4
DAP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation.PMID 28031409Read ↗

Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53.Semantic proximity Read ↗

Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.Semantic proximity Read ↗

Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 BindingSemantic proximity Read ↗

A kinetically inert platinum antitumor agent overcomes mutant p53-driven chemoresistance via oxidative stress-mediated DNA damage.Semantic proximity Read ↗

Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation.Semantic proximity Read ↗

Targeting the MDM2 ‐ MDM4 interaction interface reveals an otherwise therapeutically active wild‐type p53 in colorectal cancerSemantic proximity Read ↗

CKAP4 and mutant p53 cooperatively abrogate cell cycle checkpoint to induce genotoxic resistance in ovarian cancerSemantic proximity Read ↗

The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexesSemantic proximity Read ↗

The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death.Semantic proximity Read ↗

p28-Mediated Activation of p53 in G2–M Phase of the Cell Cycle Enhances the Efficacy of DNA Damaging and Antimitotic ChemotherapySemantic proximity Read ↗

Mutation at Ser392 specifically sensitizes mutant p53H175 to mdm2-mediated degradation.Semantic proximity Read ↗

Cdk2-dependent phosphorylation of p21 regulates the role of Cdk2 in cisplatin cytotoxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.